Stockscreener 앱 받기
16.21
9.60%
1.42
시간 외 거래:
16.20
-0.01
-0.06%
전일 마감가:
$14.79
열려 있는:
$14.79
하루 거래량:
1.50M
Relative Volume:
1.39
시가총액:
$745.86M
수익:
$159.01M
순이익/손실:
$-21.72M
주가수익비율:
-31.17
EPS:
-0.52
순현금흐름:
$-20.63M
1주 성능:
+5.53%
1개월 성능:
+21.24%
6개월 성능:
-16.70%
1년 성능:
+28.04%
1일 변동 폭
$14.79
$16.24
1주일 범위
$13.64
$16.45
52주 변동 폭
$9.215
$21.00
Axogen Inc Stock (AXGN) Company Profile
명칭
Axogen Inc
전화
(386) 462-6817
주소
13631 PROGRESS BLVD., ALACHUA, FL
AXGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AXGN
Axogen Inc
|
16.21 | 712.73M | 159.01M | -21.72M | -20.63M | -0.52 |
|
ABT
Abbott Laboratories
|
131.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.39 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.33 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.18 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
81.27 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Axogen Inc Stock (AXGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-17 | 개시 | Lake Street | Buy |
| 2024-07-01 | 개시 | Raymond James | Outperform |
| 2022-11-11 | 재개 | Jefferies | Buy |
| 2022-05-09 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2022-03-11 | 재개 | Cantor Fitzgerald | Overweight |
| 2020-10-23 | 개시 | Guggenheim | Buy |
| 2020-06-16 | 재개 | Cantor Fitzgerald | Overweight |
| 2020-05-07 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2020-04-02 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2019-08-07 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2019-07-12 | 개시 | Canaccord Genuity | Buy |
| 2018-03-02 | 재확인 | Lake Street | Buy |
| 2018-01-05 | 재개 | Cantor Fitzgerald | Overweight |
| 2017-11-30 | 개시 | Jefferies | Buy |
| 2017-11-21 | 재확인 | Lake Street | Buy |
| 2017-07-31 | 개시 | Leerink Partners | Outperform |
| 2017-06-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-03-06 | 개시 | ROTH Capital | Buy |
| 2016-11-22 | 업그레이드 | Lake Street | Hold → Buy |
| 2016-11-07 | 재확인 | Wedbush | Outperform |
| 2016-11-03 | 다운그레이드 | Lake Street | Buy → Hold |
| 2016-08-04 | 재확인 | Wedbush | Outperform |
| 2014-05-14 | 개시 | Dawson James | Buy |
| 2013-10-31 | 재확인 | Ladenburg Thalmann | Buy |
모두보기
Axogen Inc 주식(AXGN)의 최신 뉴스
Axogen (AXGN) Slid on a Weaker Than Expected Gross Margin - Yahoo Finance
AxoGen price target lowered to $20 from $21 at Raymond James - MSN
How Axogen Inc. stock performs during market volatility - sundaytimes.kr
Can Axogen Inc. grow without external funding2025 Market Overview & Expert-Curated Trade Recommendations - classian.co.kr
Does Axogen Inc. fit your quant trading modelEntry Point & Advanced Technical Signal Analysis - Newser
Tools to assess Axogen Inc.’s risk profileMarket Weekly Review & Expert Curated Trade Ideas - Newser
Short interest data insights for Axogen Inc.Watch List & Fast Entry Momentum Alerts - Newser
Raymond James Slashes PT on Axogen (AXGN) to $20 From $21 - MSN
Full technical analysis of Axogen Inc. stockWeekly Trade Review & High Win Rate Trade Alerts - Newser
How to read the order book for Axogen Inc.2025 Price Action Summary & Intraday High Probability Setup Alerts - Newser
Wall Street Analysts Predict a 76.37% Upside in AxoGen (AXGN): Here's What You Should Know - MSN
Will Axogen Inc. outperform its industry peersTrade Risk Assessment & Weekly Breakout Stock Alerts - newsyoung.net
AxoGen’s SWOT analysis: nerve repair innovator’s stock poised for growth By Investing.com - Investing.com Nigeria
AxoGen’s SWOT analysis: nerve repair innovator’s stock poised for growth - Investing.com India
Axogen Inc. Recovery Likely Here’s What Data ShowsJuly 2025 Weekly Recap & Community Shared Stock Ideas - metal.it
Axogen Inc. stock retracement – recovery analysis2025 Growth vs Value & Free Risk Controlled Daily Trade Plans - Newser
Axogen's Strategic Position in the Evolving Peripheral Nerve Repair Market: A Deep Dive into Clinical Success, Regulatory Momentum, and Growth Potential - AInvest
Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined - Seeking Alpha
Cantor Fitzgerald reiterates Overweight rating on AxoGen stock after strong Q2 By Investing.com - Investing.com South Africa
Cantor Fitzgerald reiterates Overweight rating on AxoGen stock after strong Q2 - Investing.com
Zurcher Kantonalbank Zurich Cantonalbank Invests $146,000 in AxoGen, Inc. (NASDAQ:AXGN) - Defense World
IBD Rating Upgrades: Axogen Shows Improved Price Strength - Investor's Business Daily
Leading vs lagging indicators on Axogen Inc. performanceTrade Alert System with Volume Analysis - Newser
How high can Axogen Inc. stock goSector Rotation Outlook With Historical Summary - Newser
Price momentum metrics for Axogen Inc. explainedFree Real Time Stock Movement Analysis - Newser
Axogen Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
FY2025 EPS Estimates for AxoGen Raised by Cantor Fitzgerald - Defense World
Is now a turning point for Axogen Inc.Market Forecast Summary Over Multi-Year Period - Newser
AxoGen (NASDAQ:AXGN) Upgraded to Buy at Wall Street Zen - Defense World
Can volume confirm reversal in Axogen Inc.Low Drawdown Picks with Weekly Updates - Newser
Ichimoku Cloud Indicates Uncertainty Around Axogen Inc.Expert Verified Stock Trade Ideas Backed by Data - beatles.ru
Axogen Inc Reports Strong Q2 2025 Earnings with 18.3% Revenue Growth and BLA Approval Expected in September - AInvest
AxoGen’s Earnings Call: Strong Growth Amid Challenges - The Globe and Mail
AxoGen (AXGN) Beats Q2 Earnings and Revenue Estimates - NewsBreak: Local News & Alerts
Axogen 2025 Q2 Earnings Returns to Profitability with 130.1% Net Income Jump - AInvest
Axogen raises 2025 revenue growth target to at least 17% as BLA approval nears - MSN
AxoGen, Inc. (NASDAQ:AXGN) Q2 2025 Earnings Call Transcript - Insider Monkey
Axogen Reports Strong Q2 2025 Financial Results - The Globe and Mail
How to build a custom watchlist for Axogen Inc.Free Stock Selection With High Accuracy - Newser
AxoGen: Q2 Earnings Snapshot - Stamford Advocate
Axogen Inc (AXGN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements - Investing.com Canada
Risk adjusted return profile for Axogen Inc. analyzedRisk-Managed Swing Setup and Signal Analysis - Newser
Axogen, Inc. Reports Strong Revenue Growth in Q2 2025 - TipRanks
Axogen (AXGN) Q2 Revenue Jumps 18% - AOL.com
AxoGen stock price target lowered to $20 by Raymond James on BLA timing - Investing.com Nigeria
Axogen (AXGN.O) Sees Sharp Intraday Move—What's Driving the Volatility? - AInvest
AxoGen reports Q2 adjusted EPS 12c, consensus 6c - TipRanks
AxoGen Q2 2025 Earnings Call Transcript - MarketBeat
Jefferies raises AxoGen stock price target to $25 on strong sales growth - Investing.com India
Jefferies raises AxoGen stock price target to $25 on strong sales growth By Investing.com - Investing.com South Africa
Axogen's Q2 2025 Earnings Call: Unpacking Contradictions in Margins, BLA Milestones, and Growth Strategies - AInvest
Axogen Inc (AXGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Axogen Inc 주식 (AXGN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Levine Alan M | Director |
Jun 09 '25 |
Sale |
10.61 |
4,073 |
43,215 |
36,743 |
| Wendell Amy McBride | Director |
Jun 09 '25 |
Sale |
10.61 |
4,073 |
43,215 |
93,826 |
| Burke William P. Mr. | Director |
Jun 09 '25 |
Sale |
10.61 |
4,073 |
43,215 |
24,484 |
| NEELS GUIDO J | Director |
Jun 09 '25 |
Sale |
10.61 |
4,073 |
43,215 |
86,743 |
| JOHNSON JOHN | Director |
Jun 09 '25 |
Sale |
10.61 |
4,073 |
43,215 |
24,943 |
| TYNDALL JOSEPH A. | Director |
Jun 10 '25 |
Option Exercise |
6.56 |
11,586 |
75,952 |
26,931 |
| TYNDALL JOSEPH A. | Director |
Jun 10 '25 |
Sale |
10.72 |
26,931 |
288,700 |
0 |
0.86%
0.67%
자본화:
|
볼륨(24시간):